Drug Patents owned by Tersera

1. List of Prialt drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9707270 TERSERA Method for administering ω-conopeptide
Oct, 2024

(1 year, 7 months from now)

US8653033 TERSERA Method for administering omega-conopeptide
Oct, 2024

(1 year, 7 months from now)

US8765680 TERSERA Method for administering omega-conopeptide
Oct, 2024

(1 year, 7 months from now)

Drugs and Companies using ZICONOTIDE ACETATE ingredient

Market Authorisation Date: 28 December, 2004

Treatment: Treatment of severe chronic pain via intrathecal infusion of ziconotide in patients also receiving morphine; Analgesia; Treatment of pain

Dosage: INJECTABLE;INTRATHECAL

More Information on Dosage

2. List of Qmiiz Odt drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8545879 TERSERA Fast disintegrating compositions of meloxicam
Aug, 2030

(7 years from now)

Drugs and Companies using MELOXICAM ingredient

Market Authorisation Date: 19 October, 2018

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

More Information on Dosage

3. List of Varubi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8178550 TERSERA Hydrochloride salts of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy)-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor
Apr, 2027

(4 years from now)

US7049320 TERSERA NK1 antagonists
Aug, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8796299 TERSERA NK1 antagonists
Dec, 2022

(a month ago)

US7981905 TERSERA Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-Ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same
Apr, 2027

(4 years from now)

US8404702 TERSERA Pharmaceutical formulations:salts of 8-[1-3,5-bis-(trifluoromethyl)phenyl)-ethoxymethyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same
Apr, 2027

(4 years from now)

US7563801 TERSERA Pharmaceutical formulations: salts of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same
Apr, 2027

(4 years from now)

US8470842 TERSERA Hydrochloride salts of 8-[{1-(3,5-Bis-trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor
Jan, 2029

(5 years from now)

US8361500 TERSERA Tablet formulations containing 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one salts and tablets made therefrom
Oct, 2029

(6 years from now)

US9101615 TERSERA Intravenous formulations of neurokinin-1 antagonists
Jul, 2032

(9 years from now)

Drugs and Companies using ROLAPITANT HYDROCHLORIDE ingredient

Market Authorisation Date: 01 September, 2015

Treatment: Prevention of delayed nausea and vomiting associated with emetogenic cancer chemotherapy

Dosage: TABLET;ORAL

More Information on Dosage

4. List of Xermelo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7553840 TERSERA 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
Dec, 2027

(4 years from now)

US8193204 TERSERA Solid forms of (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1- (4-chloro-2-(3-methyl-1H-pyrazol-1-YL)phenyl)2,2,2-trifluoroethoxy)-pyrimidin-4-YL)phenyl)propanoate and methods of their use
Feb, 2031

(8 years from now)

US7709493 TERSERA 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
Feb, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7968559 TERSERA Methods of using 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds
Dec, 2027

(4 years from now)

US8653094 TERSERA Solid forms of (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)-pyrimidin-4-yl)phenyl)propanoate and methods of their use
Dec, 2028

(5 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 28, 2022
Orphan Drug Exclusivity (ODE) Feb 28, 2024

Drugs and Companies using TELOTRISTAT ETIPRATE ingredient

NCE-1 date: February, 2021

Market Authorisation Date: 28 February, 2017

Treatment: The treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (ssa) therapy in adults inadequately controlled by ssa therapy

Dosage: TABLET;ORAL

More Information on Dosage

5. List of Zoladex drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7220247 TERSERA Automatically operable safety shield system for syringes
Apr, 2022

(9 months ago)

US7118552 TERSERA Automatically operable safety shield system for syringes
Apr, 2022

(9 months ago)

Drugs and Companies using GOSERELIN ACETATE ingredient

Market Authorisation Date: 11 January, 1996

Treatment: NA

Dosage: IMPLANT;IMPLANTATION

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in